Clinical Trials Logo

Acute Lymphoid Leukemia clinical trials

View clinical trials related to Acute Lymphoid Leukemia.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06427330 Not yet recruiting - Clinical trials for Acute Lymphoid Leukemia

Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Start date: May 20, 2024
Phase: Phase 2
Study type: Interventional

To learn about the safety of post-HSCT two dose Inotuzumab Ozogamicin to participants with high risk B cell acute lymphoblastic leukemia(B-ALL). Also, to learn if giving Inotuzumab Ozogamicin to post-HSCT patients with high-risk B- ALL can help to reduce relapse and prolong disease free survival and overall survival.

NCT ID: NCT05943093 Not yet recruiting - Clinical trials for Acute Lymphoid Leukemia

H19 in Acute Lymphoblastic Leukemia.

Start date: July 2023
Phase:
Study type: Observational

- Study the expression level of H19 gene in the samples from ALL patients by real-time PCR. - Correlate the expression level of H19 gene with the clinical presentation and laboratory data of those patients.

NCT ID: NCT05827549 Not yet recruiting - Clinical trials for Acute Lymphoid Leukemia

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

ReCALL
Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

This study is open-label, multi-center, prospective study, which targets childhood patients with recurred acute lymphostatic leukemia including recurrence around marrow. This study is designed to administer Idarubicin for Reinduction stage. Patients with recurrence are sorted into groups with their potential risk, and depending on their recurrence point, time, reaction to treatment etc, they are sorted into low-risk group, high-risk group, and highest-risk group. Patients with high-risk group are going to be given blinatumomab at consolidation stage before hematopoietic stem cell transplantation. Patients with low-risk group who are not suitable for hematopoietic stem cell transplantation are going to be maintaining maintenance therapy for 2 years for chemotherapy.

NCT ID: NCT02413021 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens

Start date: May 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether deferasirox is effective in the treatment of acute lymphatic leukemia (ALL) and acute Myeloid leukemia (AML).